Lifevantage (NASDAQ:LFVN) Updates FY 2026 Earnings Guidance

Lifevantage (NASDAQ:LFVN) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.600-0.800 for the period, compared to the consensus earnings per share estimate of 1.050. The company issued revenue guidance of $185.0 million-$200.0 million, compared to the consensus revenue estimate of $226.9 million.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Lifevantage from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a report on Monday, December 29th. Finally, Lake Street Capital reiterated a “buy” rating and set a $12.00 price target on shares of Lifevantage in a report on Wednesday, November 5th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Lifevantage Stock Performance

Lifevantage stock traded up $0.19 during mid-day trading on Wednesday, reaching $5.55. 303,823 shares of the company were exchanged, compared to its average volume of 232,395. The firm has a market cap of $70.49 million, a PE ratio of 7.21 and a beta of 0.33. The firm’s 50-day simple moving average is $6.22 and its two-hundred day simple moving average is $8.96. Lifevantage has a twelve month low of $5.15 and a twelve month high of $24.05.

Lifevantage (NASDAQ:LFVN) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.07). The business had revenue of $48.93 million during the quarter, compared to analysts’ expectations of $54.40 million. Lifevantage had a net margin of 4.43% and a return on equity of 33.52%. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.

Insiders Place Their Bets

In other Lifevantage news, Director Michael A. Beindorff sold 35,000 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $6.92, for a total transaction of $242,200.00. Following the completion of the transaction, the director owned 56,413 shares of the company’s stock, valued at approximately $390,377.96. This trade represents a 38.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 48,607 shares of company stock valued at $330,467. Company insiders own 21.95% of the company’s stock.

More Lifevantage News

Here are the key news stories impacting Lifevantage this week:

• Positive Sentiment: Board approved a quarterly cash dividend of $0.045 per share, payable March 16, 2026 — a shareholder‑friendly move that can support the share price and attract income investors. Article Title
• Positive Sentiment: Company announced the planned retirement of CEO Steve Fife along with a CEO succession plan — an orderly transition can reduce leadership uncertainty if investors view the plan as well‑managed. Article Title
• Neutral Sentiment: Full Q2 2026 earnings call / transcript published — useful for investors wanting management commentary on drivers of the quarter, the guidance cut, and the succession timeline. Article Title
• Negative Sentiment: Quarterly results missed expectations: reported EPS $0.15 vs. consensus ~$0.22 and revenue $48.9M (well below estimates). Management cut FY‑2026 guidance to EPS $0.60–0.80 (consensus ~1.05) and revenue $185–200M (consensus ~226.9M) — a material reduction that explains significant selling pressure. Article Title
• Negative Sentiment: Underlying operating trends weakened sharply: revenue down ~27.8% YoY, gross profit down ~33.6%, net income and cash from operations materially lower, and cash balances down — these metrics raise short‑ to medium‑term execution and liquidity concerns. Article Title

Institutional Investors Weigh In On Lifevantage

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new position in shares of Lifevantage during the first quarter valued at approximately $97,000. Jones Financial Companies Lllp lifted its stake in shares of Lifevantage by 14,484.0% during the 1st quarter. Jones Financial Companies Lllp now owns 29,168 shares of the company’s stock worth $425,000 after purchasing an additional 28,968 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Lifevantage by 24.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 44,518 shares of the company’s stock worth $649,000 after purchasing an additional 8,762 shares during the period. Jane Street Group LLC boosted its holdings in shares of Lifevantage by 5.4% during the first quarter. Jane Street Group LLC now owns 36,567 shares of the company’s stock worth $533,000 after purchasing an additional 1,877 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Lifevantage by 106.1% in the second quarter. Geode Capital Management LLC now owns 245,332 shares of the company’s stock valued at $3,210,000 after purchasing an additional 126,274 shares during the period. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.